Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide

D. Bengtsson; H. D. Schrøder; K. Berinder; D. Maiter; C. Hoybye; O. Ragnarsson; U. Feldt-Rasmussen; Rasmussen Krogh Rasmussen; A. van der Lely; M. Petersson; G. Johannsson; M. Andersen; P. Burman

doi:10.1007/s12020-018-1751-9

Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide

D. Bengtsson, H. D. Schrøder, K. Berinder, D. Maiter, C. Hoybye, O. Ragnarsson, U. Feldt-Rasmussen, Rasmussen Krogh Rasmussen, A. van der Lely, M. Petersson, G. Johannsson, M. Andersen, P. Burman^*

^*Corresponding author af dette arbejde

Institut for Klinisk Medicin

12 Citationer (Scopus)

Originalsprog	Engelsk
Tidsskrift	Endocrine
Vol/bind	62
Udgave nummer	3
Sider (fra-til)	737-739
Antal sider	3
ISSN	1355-008X
DOI	https://doi.org/10.1007/s12020-018-1751-9
Status	Udgivet - 2018

Adgang til dokumentet

10.1007/s12020-018-1751-9

Citationsformater

Bengtsson, D., Schrøder, H. D., Berinder, K., Maiter, D., Hoybye, C., Ragnarsson, O., Feldt-Rasmussen, U., Krogh Rasmussen, R., van der Lely, A., Petersson, M., Johannsson, G., Andersen, M., & Burman, P. (2018). Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide. Endocrine, 62(3), 737-739. https://doi.org/10.1007/s12020-018-1751-9

Bengtsson, D, Schrøder, HD, Berinder, K, Maiter, D, Hoybye, C, Ragnarsson, O, Feldt-Rasmussen, U, Krogh Rasmussen, R, van der Lely, A, Petersson, M, Johannsson, G, Andersen, M & Burman, P 2018, 'Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide', Endocrine, bind 62, nr. 3, s. 737-739. https://doi.org/10.1007/s12020-018-1751-9

@article{46585e23da7e4d8d95124a45c80e5e08,

title = "Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide",

author = "D. Bengtsson and Schr{\o}der, {H. D.} and K. Berinder and D. Maiter and C. Hoybye and O. Ragnarsson and U. Feldt-Rasmussen and {Krogh Rasmussen}, Rasmussen and {van der Lely}, A. and M. Petersson and G. Johannsson and M. Andersen and P. Burman",

year = "2018",

doi = "10.1007/s12020-018-1751-9",

language = "English",

volume = "62",

pages = "737--739",

journal = "Endocrine",

issn = "1355-008X",

publisher = "Humana Press",

number = "3",

}

TY - JOUR

T1 - Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide

AU - Bengtsson, D.

AU - Schrøder, H. D.

AU - Berinder, K.

AU - Maiter, D.

AU - Hoybye, C.

AU - Ragnarsson, O.

AU - Feldt-Rasmussen, U.

AU - Krogh Rasmussen, Rasmussen

AU - van der Lely, A.

AU - Petersson, M.

AU - Johannsson, G.

AU - Andersen, M.

AU - Burman, P.

PY - 2018

Y1 - 2018

U2 - 10.1007/s12020-018-1751-9

DO - 10.1007/s12020-018-1751-9

M3 - Letter

C2 - 30246233

AN - SCOPUS:85053657322

SN - 1355-008X

VL - 62

SP - 737

EP - 739

JO - Endocrine

JF - Endocrine

IS - 3

ER -